Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation, Incyte Corporation, and PharmaEssentia USA.

2nd Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis

Release Date: May 30, 2020
Expiration Date: May 30, 2021

Activity Overview

This online educational activity consists of a series of videos from a previously live webcast designed to explore current trends in prognostic scoring, molecular diagnostics, and appropriate guideline-based management of myeloproliferative neoplasms (MPNs), as well as current and emerging therapeutic strategies of an array of agents including JAK inhibitors and interferons. By applying evidence in real-world case scenarios, this program contextualizes that evidence to ensure that practitioners are up-to-date with the evolving treatment landscape of polycythemia vera (PV) and myelofibrosis (MF), including current clinical trial findings, evolving treatment paradigms, and the mechanistic rationale for novel therapeutic approaches in the context of MPN pathophysiology. The program is designed to aid physicians in assessing the wealth of emerging data in treating MPNs, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation, Incyte Corporation, and PharmaEssentia USA.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with MPNs. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of MPNs may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the latest discoveries in the biology of myelofibrosis (MF) and polycythemia vera (PV) and its potential impact on clinical decision-making.
  • Explain current clinical management strategies for patients with MF and PV.
  • Summarize ongoing clinical trials and their potential impact to the treatment landscape of MF and PV.
  • Implement multidisciplinary strategies to effectively counsel patients with MF and PV concerning treatment-related toxicities and management of disease-related symptoms.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Ronald Hoffman, MD
Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Director, Myeloproliferative Disorders Research Program
Tisch Cancer Institute
Icahn School of Medicine
New York, NY

Disclosures: Ronald Hoffman, MD has no relevant financial relationships with commercial interests.

Gillian Sanchez, MPH, BSN, RN
Gillian Sanchez, MPH, BSN, RN
Clinical Research Program Manager
Adult Leukemia Program
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Gillian Sanchez MPH, BSN, RN has no relevant financial relationships with commercial interests.

John Mascarenhas, MD
John Mascarenhas, MD
Director, Adult Leukemia Program
Leader, MPN Clinical Research
Tisch Cancer Institute
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: Arog, CTI Biopharma, Incyte, Roche, Novartis, Merck, Janssen, Promedia; Consultant: Roche, Celgene, Prelude, Promedia, Constellation.

Joseph Michael Scandura, MD, PhD
Joseph Michael Scandura, MD, PhD
Associate Professor of Medicine
Scientific Director, Silver Myeloproliferative Disease Center
Division of Hematology and Oncology
Division of Regenerative Medicine
Weill Cornell Medicine
New York, NY

Disclosures: Grant Research Support: (All Grants and Support to Institution) Incyte, Constellation, AbbVie, CTI Biopharma, Genentech, MedPacto, Protagonist Therapeutics.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By